Abstract:Abstract Background Eosinophilic esophagitis (EoE) is a Th2 driven chronic, inflammatory disorder defined by esophageal dysfunction and a peak eosinophil count (PEC) ≧ 15 eosinophils/high-power field on biopsy. Dupilumab, a human monoclonal antibody that inhibits IL-4 and IL-13 signaling was recently approved for use in Canada in children with EoE. There is limited data on the histologic abnormalities found with reintroduction of dietary triggers on dupilumab. Aims To describe emergence of lymphocytic esophagitis without eosinophilia observed during food reintroduction in a pediatric patient with EoE on dupilumab. Methods Case report and literature review. Results We present a 14-year-old boy with extensive food allergies, eczema, asthma and treatment refractory EoE. After failing to improve with proton-pump inhibitor (PPI), food elimination diet and topical steroids, he was started on an elemental formula with concomitant PPI. This resulted in symptomatic and histologic remission, however food restriction led to poor quality of life. The patient was started on dupilumab 200 mg every 2 weeks and had a dramatic improvement in his disease course. Over 2 years on treatment, several allergic foods were reintroduced with normal histologic biopsies. However, two dietary challenges led to the emergence of lymphocytic esophagitis with basal zone hyperplasia (BZH) and dilated intercellular spaces (DIS), but no eosinophilia. Subsequent removal of the dietary antigen and endoscopic reassessment led to normal biopsies, without lymphocytic or eosinophilic infiltration. Lymphocytic esophagitis is rare in children and the etiology is unknown; it is characterized by increased intraepithelial lymphocytes without eosinophils or neutrophils, and associated spongiosis. The emergence of lymphocytic esophagitis was unexpected and subsequent normalization of histology with removal of an antigen suggests that the lymphocytic pattern observed was driven by the allergic food. This may indicate that IL-4/IL-13 antagonism by dupilumab affects other immune signaling pathways, resulting in a lymphocytic-predominant inflammatory response upon exposure to allergic food antigens. Conclusions Dupilumab is a promising new medication in the management of pediatric EoE, particularly in the extremely atopic patient. In our case, the use of dupilumab led to improved antigen tolerance and quality of life. However, the emergence of lymphocytic esophagitis was unexpected, and the natural history and prognosis of this condition is not well defined. This is the first case to describe the emergence of lymphocytic esophagitis in a patient treated for eosinophilic esophagitis with dupilumab, and its subsequent resolution with dietary exclusion. Funding Agencies None

Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders

Successful use of dupilumab for egg-induced eosinophilic gastroenteritis with duodenal ulcer: a pediatric case report and review of literature

Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center

Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and EGID with esophageal involvement

S661 Dupilumab Improves Multiple Histopathologic Endpoints in Children With Eosinophilic Esophagitis: 52-Week Results From the Phase 3 EoE KIDS Trial

Real-world effectiveness and use of dupilumab in eosinophilic esophagitis

A218 TRADING ONE PROBLEM FOR ANOTHER? THE EMERGENCE OF LYMPHOCYTIC ESOPHAGITIS IN A PEDIATRIC PATIENT WITH EOSINOPHILIC ESOPHAGITIS AFTER TREATMENT WITH DUPILUMAB

Successful novel use of dupilumab for gastrointestinal involvement of idiopathic hypereosinophilic syndrome: case report and review of the literature

Real‐world efficacy of dupilumab in four cases of paediatric‐onset fibrostenotic eosinophilic esophagitis

Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis

Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review

Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting

Dupilumab as Therapeutic Option in Polysensitized Atopic Dermatitis Patients Suffering from Food Allergy

Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence

Symptomatic Improvement in Adults and Adolescents with Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure than Histologic Response

Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report

Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab

Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age

The Changes of IgE Levels in Type 2 Inflammatory Diseases after Treatment of Dupilumab: a Systematic Review and Meta-Analysis

Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis